Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2008

View Archived Issues

Hedgehog pathway inhibitor shows potential benefits in cancer models

LRG-47: a novel therapeutic target in multiple sclerosis

Low relapse rate and MRI activity in MS with oral FTY-720 in 30-month extension study

Lumiliximab activity is independent of antigen expression levels in lymphocytic leukemia cells

Nippon Shinyaku receives approval for dysmenorrhea agent in Japan

ABT-263 improves oral bioavailability and potency of Bcl-2 family protein inhibitors

Schering-Plough receives Japanese approval for Aroglycem

ARRY-520 enters phase I/II clinical evaluation

JAK2 inhibitor INCB-18424 to be evaluated in phase II studies

Boston Scientific receives Canadian approval for sale of Taxus Liberte coronary stent

BrainCells initiates phase II clinical trial of BCI-540 for depression with anxiety

Novel antithrombotic agents disclosed in recent Portola patent

Recent Schering patents divulge new analgesic agents

Romark initiates enrollment in phase II clinical trial of Alinia in hepatitis C

Preclinical activity of Aurora kinase B/C inhibitor GSK-1070916A described

CD-200-Fc significantly improves arthritis in mouse model

Alseres opens seven enrollment sites for first stage of Altropane phase III clinical trial program

Innocoll initiates dosing in phase II clinical trial of CollaRx gentamicin topical sponge

CSL Behring submits NDS to Health Canada for approval of C1-esterase inhibitor for HAE

Raptor initiates phase IIa Convivia study in subjects with ALDH2 deficiency

Thalidomide Pharmion granted E.U. marketing authorization for multiple myeloma

Recent Speedel patent reports novel antihypertensive agents

Sutent approved in Japan for GIST and renal cell carcinoma

Champix set for Japanese launch

Bayer launches Nexavar in Japan for recurrent renal carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...